The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Open accessAbstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). The study aimed to enroll 400 subjects with early mild cognitive impairment (MCI), 200 subjects with early AD, and 200 normal control subjects; $67 million funding was provided by both the public and private sectors, including the National Institute on Aging, 13 pharmaceutical companies, and 2 foundations that provided support through the Foundation for the National Institutes of Health. This article reviews all papers published since the inception of the initiative and summarizes the results as of February 2011. The major accomplishments of ADNI have been as follows: (1) the development of standardized methods for clinical tests, magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting; (2) elucidation of the patterns and rates of change of imaging and CSF biomarker measurements in control subjects, MCI patients, and AD patients. CSF biomarkers are consistent with disease trajectories predicted by β‐amyloid cascade (Hardy, J Alzheimers Dis 2006;9(Suppl 3):151–3) and tau‐mediated neurodegeneration hypotheses for AD, whereas brain atrophy and hypometabolism levels show predicted patterns but exhibit differing rates of change depending on region and disease severity; (3) the assessment of alternative methods of diagnostic categorization. Currently, the best classifiers combine optimum features from multiple modalities, including MRI, [18 F]‐fluorodeoxyglucose‐PET, CSF biomarkers, and clinical tests; (4) the development of methods for the early detection of AD. CSF biomarkers, β‐amyloid 42 and tau, as well as amyloid PET may reflect the earliest steps in AD pathology in mildly symptomatic or even nonsymptomatic subjects, and are leading candidates for the detection of AD in its preclinical stages; (5) the improvement of clinical trial efficiency through the identification of subjects most likely to undergo imminent future clinical decline and the use of more sensitive outcome measures to reduce sample sizes. Baseline cognitive and/or MRI measures generally predicted future decline better than other modalities, whereas MRI measures of change were shown to be the most efficient outcome measures; (6) the confirmation of the AD risk loci CLU, CR1, and PICALM and the identification of novel candidate risk loci; (7) worldwide impact through the establishment of ADNI‐like programs in Europe, Asia, and Australia; (8) understanding the biology and pathobiology of normal aging, MCI, and AD through integration of ADNI biomarker data with clinical data from ADNI to stimulate research that will resolve controversies about competing hypotheses on the etiopathogenesis of AD, thereby advancing efforts to find disease‐modifying drugs for AD; and (9) the establishment of infrastructure to allow sharing of all raw and processed data without embargo to interested scientific investigators throughout the world. The ADNI study was extended by a 2‐year Grand Opportunities grant in 2009 and a renewal of ADNI (ADNI‐2) in October 2010 through to 2016, with enrollment of an additional 550 participants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Neuroimaging to assess safety and efficacy of AD therapies
Hill, D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381320 · Cited by 28
Statistical analysis of relative pose information of subcortical nuclei: Application on ADNI data
Bossa, M. N., Zacur, E., & Olmos, S. C. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.078 · Cited by 25
Epstein, N. U., Saykin, A. J., Risacher, S. L., Gao, S., & Farlow, M. R. (2010) · Drugs & Aging · doi:10.2165/11538260-000000000-00000 · Cited by 22
Self-citationApplications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease
Fleisher, A., Donohue, M., Chen, K., Brewer, J. B., Aisen, P. S. S., & Initiative, T. A. D. N. (2009) · Behavioural Neurology · doi:10.1155/2009/836437 · Cited by 22
Self-citationAlzheimers Disease Drug Development: Old Problems Require New Priorities
Becker, R. E., & Greig, N. H. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708787122950 · Cited by 21
Maximizing the Alzheimer's Disease Neuroimaging Initiative II
Carrillo, M. C., Sanders, C. A., & Katz, R. G. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.02.005 · Cited by 20
Wu, X., Chen, K., Yao, L., Ayutyanont, N., Langbaum, J. B. S., Fleisher, A., Reschke, C., Lee, W., Liu, X., Alexander, G. E., et al. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.07.030 · Cited by 18
Self-citationConsistent 4D Cortical Thickness Measurement for Longitudinal Neuroimaging Study
Initiative, T. A. D. N., Li, Y., Wang, Y., Xue, Z., Shi, F., Lin, W., & Shen, D. G. (2010) · Lecture notes in computer science · doi:10.1007/978-3-642-15745-5_17 · Cited by 17
Park, H., & Seo, J. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.10.019 · Cited by 16
Basics of Multivariate Analysis in Neuroimaging Data
Habeck, C. G. (2010) · Journal of Visualized Experiments · doi:10.3791/1988-v · Cited by 15
Geriatric Medicine, Japanese Alzheimer's Disease Neuroimaging Initiative and Biomarker Development
Arai, H., Okamura, N., Furukawa, K., & Kudo, Y. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.87 · Cited by 14
Data Fusion and Feature Selection for Alzheimer’s Diagnosis
Lemoine, B., Rayburn, S., & Benton, R. (2010) · Lecture notes in computer science · doi:10.1007/978-3-642-15314-3_30 · Cited by 13
Discrimination of AD and normal subjects from MRI: Anatomical versus statistical regions
Peláez‐Coca, M. D., Bossa, M. N., & Olmos, S. C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.007 · Cited by 13
Schmidt, M. E., Siemers, E., Snyder, P. J., Potter, W. Z., Cole, P. E., & Soares, H. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.010 · Cited by 11
Self-citationvan Gils, M., Koikkalainen, J. R., Mattila, J., Herukka, S., Lötjönen, J. M. P., & Soininen, H. (2010) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2010.5626311 · Cited by 10
Standing on the Shoulders of Giants: Improving Medical Image Segmentation via Bias Correction
Wang, H., Das, S. R., Pluta, J. B., Craige, C. P., Altinay, M. I., Avants, B., Weiner, M. W., Mueller, S. G., & Yushkevich, P. A. (2010) · Lecture notes in computer science · doi:10.1007/978-3-642-15711-0_14 · Cited by 9
Self-citationICA-Based Automatic Classification of Magnetic Resonance Images from ADNI Data
Yang, W., Chen, X., Xie, H., & Huang, X. (2010) · Lecture notes in computer science · doi:10.1007/978-3-642-15615-1_41 · Cited by 9
Obesity and the brain: a possible genetic link
Bertram, L., & Heekeren, H. R. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt51 · Cited by 8
[Alzheimer's disease neuroimaging initiative and mild cognitive impairment].
Arai, H. (2007) · PubMed · Cited by 7
[Overview on Alzheimer's disease].
Ihara, Y. (2007) · PubMed · Cited by 6
[Neuropathology of mild cognitive impairment Alzheimer's disease].
Murayam, S., & Saito, Y. (2007) · PubMed · Cited by 6
[Neuroimaging in mild cognitive impairment].
Fukuyama, H. (2006) · PubMed · Cited by 5
Cited by
The cognitive neuroscience of ageing
Grady, C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3256 · Cited by 1,286
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationMagnetoencephalography for Brain Electrophysiology and Imaging
Baillet, S. (2017) · Nature Neuroscience · doi:10.1038/nn.4504 · Cited by 992
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data
the Alzheimer’s Disease Neuroimaging Initiative, E. C., Thompson, P. M., Stein, J. L., Medland, S. E., Hibar, D. P., Vasquez, A. A., Renteria, M. E., Toro, R., Jahanshad, N., Schumann, G., et al. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9269-5 · Cited by 838
Self-citationHistory and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Metadata
- Authors
- Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., Morris, J. C., Petersen, R. C., Saykin, A. J., Schmidt, M. E., Shaw, L., Siuciak, J. A., Soares, H., Toga, A. W., Trojanowski, J. Q., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-11-03
- Volume
- 8
- Issue
- 1S
- Pages
- S1-68
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W4249565903
- Cited by
- 476
- References
- 222
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.